President Trump will continue to pursue the policy of Medicare pricing negotiation introduced by former President Biden's Inflation Reduction Act (IRA), but will look at refining the programme.

Robert F Kennedy Jr's first confirmation hearing was a fractious affair, marked by tough questions about his prior ...

In a new pharmaphorum podcast with ZS Associates’ Sharon Karlsberg, principal and leader of oncology solutions, and Brandi Davis-Dusenbery, principal and partner, web editor Nicole Raleigh explores ...

In Part 6 of the Life Sciences Industry Report, we’ve collated key thought leadership from 2024 that looks at ways in which ...

Featuring three days of data-driven sessions from 25+ world-class speakers, the 3rd Precision Medicine in Inflammatory Bowel Disease returns as the field’s most comprehensive learning and networking ...

The growing use of AI has opened new avenues for healthcare marketers, revolutionising how they approach new initiatives. With the Pharma 4.0 term representing the pharmaceutical industry's adaptation ...

Misinformation is becoming more prevalent with the rise of unregulated social media content. Combatting this and helping men distinguish between credible sources and misleading or false information is ...

The industry is grappling with significant market shifts amidst emerging technologies and changing demands. Companies are now producing increasingly personalised and sophisticated therapies, ...

One explanation for the findings is that ECG data can help to predict the risk of stroke, which can contribute to age-related ...

Weber said it is the right time to appoint a successor, given the company's "competitive growth outlook, new product launches ...

Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug for sight-robbing disease geographic atrophy (GA) into pivotal testing.

Thyroid eye disease (TED) therapy Tepezza – the top asset in Amgen's $26 billion takeover of Horizon in 2023 – could be facing competition from an easier-to-dose alternative from Sling ...